Distinguished in Primary Hyperoxaluria Type 1

Gesa Schalk

Bonn, NW, DE 
Distinguished in Primary Hyperoxaluria Type 1
Bonn, NW, DE 
OverviewLocationsClinical Research

Overview

Gesa Schalk practices in Bonn, Germany. Schalk is rated as a Distinguished expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. Their top areas of expertise are Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Nephrocalcinosis, and Kidney Stones.

Their clinical research consists of co-authoring 13 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Primary Hyperoxaluria Type 1.

Locations

Bonn, NW, Germany
Other Locations
Koeln, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Enrollment Status: Completed
Publish Date: December 10, 2021
Intervention Type: Other, Biological
Study Drug: Oxabact OC5 - Oxalobacter formigenes HC-1
Study Phase: Phase 3
An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02
An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Biological
Study Drug: Oxabact OC5 - Oxalobacter formigenes Strain HC-1
Study Phase: Phase 3
View 1 Less Clinical Trial

13 Total Publications

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.
PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.
Journal: Kidney international reports
Published: December 20, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Schalk's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile